International Journal of Hepatology / 2012 / Article / Tab 3

Clinical Study

Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States

Table 3

Univariate and multivariate analysis.

FactorsHR (95% CI)PHR (95% CI)P

Age1.02 (1.01–1.03)0.0051.02 (1.01–1.03)0.002
Gender 0.03 0.11
 Female 1.0 1.0
 Male 0.80 (0.65–0.98)0.031.20 (0.96–1.49)0.11
Diabetes mellitus 0.29
 No*1.0 N/AN/A
 Yes1.11 (0.91–1.36)0.29
BMI1.00 (0.98–1.02)0.72N/AN/A
Number of tumors 0.78
 1 1.0
 2 0.95 (0.77–1.17) 0.63 N/AN/A
 30.91 (0.67–1.24)0.55
Total Tumor Diameter1.08 (1.01–1.16)0.021.09 (1.01–1.18)0.03
Liver directed therapy 0.04 0.06
 No 1.0 1.0
 Yes0.82 (0.67–0.99)0.041.22 (0.99–1.50)0.06
Hepatitis B virus 0.47
 Negative 1.0 N/AN/A
 Positive0.93 (0.77–1.13)0.47
Hepatitis C virus 0.02 0.004
 Negative 1.0 1.0
 Positive1.26 (1.03–1.54)0.021.34 (1.10–1.64)0.004
Transplant criteria 0.22 0.32
 Milan 1.0 1.0
 UCSF1.34 (0.84–2.15)0.221.31 (0.77–2.21)0.32

*Yes: type I or II; or type unknown.
HR: hazard ratio; CI: confidence interval; BMI: body mass index.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.